Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 294

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 294
---
 Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    17,992

    (11,559
    )

    Deferred offering costs

    71,133

    82,071

    Accounts payable

    (576,277
    )

    749,660

    Accrued expenses

    (2,935,920
    )

    161,963

    Net cash used in operating activities

    (18,321,276
    )

    (7,286,286
    )

    Cash flows from investing activities:

    Purchase of property and equipment

    (19,171
    )

    —

    Net cash used in investing activities

    (19,171
    )

    —

    Cash flows from financing activities:

    Proceeds from the February 2024 Public Offering, net

    5,417,053

    —

    Proceeds from the Class D Common Stock Warrants exercises

    241,390

    —

    Proceeds from Warrant Inducement exercises, net

    3,501,276

    —

    Proceeds from Class D Pre-Funded Warrants exercise

    127

    —

    Proceeds from the Class E Common Stock Warrants exercises

    3,687,918

    —

    Redemption of Series A Preferred Stock

    —

    (5,000
    )

    Proceeds from the February 2023 Public Offering, net

    —

    14,029,974

    Proceeds from Class C Pre-Funded Warrants exercise

    —

    34

    Net cash provided by financing activities

    12,847,764

    14,025,008

    Net (decrease) increase in cash and cash equivalents

    (5,492,683
    )

    6,738,722

    Cash and cash equivalents at beginning of period

    11,991,701

    5,252,979

    Cash and cash equivalents at end of period
     
    $
    6,499,018

    $
    11,991,701

    Supplemental disclosure of non-cash investing and financing activities:

    Fair Value of Class G Common Stock Warrants
     
    $
    2,066,429

    $
    —

    Fair Value of Class F Common Stock Warrants
     
    $
    4,104,680